Scientists have identified a peptide, BRP, that reduced food intake by up to 50% in animal studies, offering a potential new avenue for obesity and diabetes treatment.
BRP: A Potential “Natural Ozempic”
Researchers have discovered a peptide called BRP (BRINP2-related peptide) that demonstrates significant appetite-suppressing effects in animal models, leading to comparisons with the drug Ozempic. While human trials are yet to be conducted, the findings, published in Nature, suggest a novel approach to controlling hunger and combating obesity and diabetes.
Unlike semaglutide, the active substance in Ozempic and Wegovy, BRP appears to operate through a different mechanism, sparking considerable interest in its potential for treating obesity and metabolic disorders.
How Was BRP Discovered?
BRP is a short peptide consisting of 12 amino acids, identified as potentially important for regulating appetite and energy balance. Researchers utilized artificial intelligence to sift through precursor proteins, seeking active peptides with hormonal effects. This highlights the potential for AI to drive the development of new anti-obesity therapies beyond the established GLP-1 pathway.
The Role of Artificial Intelligence
A team at Stanford University developed an algorithm called Peptide Predictor to identify fragments within larger proteins that could form biologically active peptides after cleavage. The process involved multiple stages, beginning with AI prediction and culminating in laboratory testing, where BRP emerged as a particularly promising candidate.
Appetite Suppression in Animal Studies
BRP significantly reduced appetite in mice and miniature pigs. A single dose of BRP administered before feeding decreased food intake by up to 50% within an hour in lean mice and pigs. This is a crucial observation, as reducing hunger is a primary goal of modern obesity treatment.
Miniature pigs are particularly relevant in these studies because their metabolism and eating patterns more closely resemble those of humans than mouse models, although direct translation to humans remains uncertain.
Weight Loss and Metabolic Improvements
In obese mice, BRP administration over 14 days resulted in an average weight loss of approximately 3 grams, while the control group gained about 3 grams. Importantly, the weight loss primarily consisted of fat tissue.
The study also noted improvements in two key metabolic parameters, enhancing the significance of the discovery, though it doesn’t yet indicate a ready-to-use therapy for diabetes.
BRP vs. Ozempic: Differences in Mechanism
Comparisons to Ozempic arise from semaglutide’s prominence as an appetite- and weight-influencing drug. However, researchers emphasize that BRP doesn’t function like GLP-1 drugs. Semaglutide affects the brain, digestive tract, pancreas, and other tissues, while BRP appears to act more selectively within the hypothalamus, the brain region controlling hunger and metabolism.
This distinct mechanism could open the door to a new class of therapies.
Safety Profile and Side Effects
Notably, BRP did not induce some of the side effects associated with GLP-1 medications in animal studies. Researchers observed no changes in the animals regarding blood glucose levels, heart rate, or body temperature.
Furthermore, BRP did not cause symptoms like nausea, constipation, or significant muscle loss, commonly linked to semaglutide. However, these observations are currently limited to animal studies, and the safety profile in humans remains unknown.
Future Research and Clinical Trials
While the results are promising, the research is currently preclinical and does not involve human subjects. Extensive further testing is required, including assessing the peptide’s efficacy and safety in human clinical trials, before it can be considered a viable therapy.
Researchers plan to continue investigating BRP’s mechanism of action and explore ways to prolong its activity within the body, a crucial step towards potential drug development.
Potential Beyond Obesity
The findings are primarily relevant to obesity treatment, but their implications may extend further. Improved glucose tolerance and insulin sensitivity suggest that BRP could also be a valuable topic in research on metabolic disorders linked to excess weight.
This doesn’t necessarily mean BRP will become a diabetes drug, but it highlights its influence on processes crucial for glucose metabolism, fueling significant interest in the discovery.
